May 22, 2017 / 3:40 PM / 2 months ago

BRIEF-Merck announces presentation of phase 2 results for MK-7264

1 Min Read

May 22 (Reuters) - Merck & Co Inc

* Merck announces presentation of phase 2 results for MK-7264, an investigational, p2x3 receptor antagonist, being evaluated for the treatment of chronic cough

* Highest dose evaluated, 50 mg, reduced awake cough frequency primary endpoint, by 37 percent from baseline relative to placebo

* Lower doses (7.5 mg and 20 mg) were not statistically significant

* Merck plans to discuss results and phase 3 clinical development plan for MK-7264 with regulatory agencies later this year

* One patient in placebo group and six patients in 50 mg treatment group discontinued due to taste-related adverse events Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below